VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trial VTP-1000 was well-tolerated with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback